Monoclonal Antibody Development for Brain Tumors
Monoclonal antibody drugs are therapeutic agents that use the natural immune system function to fight cancer. Monoclonal antibodies are laboratory-produced molecules designed to be used as replacement antibodies that restore, enhance or mimic the immune system's attack on cancer cells. Monoclonal antibodies have evolved from scientific tools to powerful treatments for a wide range of diseases including cardiovascular, respiratory, hematological, immunological, and malignancies. The delivery of monoclonal antibodies to the central nervous system (CNS) is a challenging task due to the limitations of the blood-brain barrier.
We provide drug development services for monoclonal antibodies targeting brain tumors
Alfa Cytology provides monoclonal antibody drug development services for brain tumors. By encapsulating monoclonal antibodies in nanocapsules containing choline and acetylcholine analogs, we enable the nanocapsules to cross the blood-brain barrier and deliver monoclonal antibodies to the tumor site. It can effectively improve the therapeutic effects of monoclonal antibodies for various brain tumors.
ADC development services for brain tumors
Antibody-drug couples (ADC) are a new class of highly effective biologic drugs formed by linking antibodies to biologically active drug components. This strategy of combining the high specificity of monoclonal antibody drugs with the high activity of small molecule cytotoxic drugs can improve the targeting and reduce the toxic effects of brain tumor drugs. While early ADC has limited success and high toxicity in brain tumor patients, Alfa Cytology is updating and improving ADC with the goal of lower immunogenicity and more payload. Our goal is to overcome the various factors affecting ADC targeting of brain tumors to improve their efficacy and therapeutic potential in brain tumors.
Bispecific antibody development for brain tumors
Bispecific antibodies (BsAb) are artificial antibodies that can bind two different specific antigens at the same time, bridging the gap between target cells and functional molecules (cells) and stimulating a directed immune response. This bi-specificity of BsAb means that one antigen-binding site can be used to bind to the target cell while the other antigen-binding site can be used to recruit other cells or molecules. Alfa Cytology utilizes a unique immune cell bridger platform that allows us to rapidly develop BsAb molecules that are redirected by immune cells to the brain tumor microenvironment. In addition, we can provide you with fast and efficient BsAb expression services using our optimized and proven mammalian cell expression platform.
Brain tumors, including primary brain tumors (e.g., gliomas) and metastatic brain tumors, are among the most serious CNS diseases, characterized by rapid progression, high recurrence rates, and short median survival times. Therefore, in addition to developing effective monoclonal antibodies for our customers, Alfa Cytology offers highly specific delivery systems to deliver therapeutic monoclonal antibodies to the CNS, which holds great promise for the treatment of brain tumors. Please contact us to learn how we can provide you with monoclonal antibody development and delivery services.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Services
